Multidrug-resistant tuberculosis (MDR-TB) refers to the case when a clinical TB isolate is resistant to two of the most potent tuberculosis medications: isoniazid and rifampin. Globally, there are about half a million new cases of MDR-TB per year. Prof. Timothy Rodwell (UC San Diego, San Diego, CA, US) talked to us about the advantages, efficacy and cost-effectiveness of next-generation sequencing in making treatment decisions for patients with drug resistant TB.
‘Shedding Light on New MDR-TB Treatment Decisions with Next Generation Sequencing’ was presented at the annual International Conference on Emerging Infectious Diseases (ICEID), August 7–10, 2022.
- What are the advantages of next-generation sequencing in making treatment decisions in tuberculosis (MDR-TB)? (00:22)
- What clinical evidence supports the efficacy of next-generation sequencing in treatment decisions in tuberculosis? (02:23)
- What clinical evidence supports the cost-effectiveness of next-generation sequencing in treatment decisions in tuberculosis? (05:02)
Disclosures: Timothy Rodwell serves as a consultant for FIND; he receives grant/research support from NIH, DoD; he is a major stock shareholder in Verus Diagnostics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Marianna Mignani.
Filmed as a highlight of ICEID 2022.
